Impact of Preadmission Beta-blocker Use on Cardiac Abnormalities and In-hospital Mortality in Patients with Aneurysmal Subarachnoid Hemorrhage

Authors

Toshimasa Okabe, MD, Ohio State University Wexner Medical CenterFollow
Anushya Jeyabalan, MD, Tufts Medical Center
Benjamin E. Leiby, PhD, Thomas Jefferson University HospitalFollow
Fred Rincon, MD, Thomas Jefferson UniversityFollow
Walter K. Kraft, MD, Thomas Jefferson UniversityFollow

Document Type

Poster

Publication Date

10-25-2014

Comments

Poster presented at 2014 International Heart & Brain Summit, Columbus, Ohio, October 25, 2014.

Allied manuscript:

Okabe T, Kanzaria M, Rincon F, Kraft WK. Cardiac Abnormalities after Subarachnoid Hemorrhage: The Role of Cardiovascular Protection to Improve Clinical Outcome. Neurocritical Care. 2013;18(2):271-84. [PMID: 23238984]

Abstract

Introduction:

Various cardiac abnormalities, including dysrhythmias, left ventricular (LV) dysfunction, and myocardial injury, are commonly seen after subarachnoid hemorrhage (SAH). In patients taking a beta-blocker (BB) chronically, the medication is generally discontinued after hospitalization due to the concern of compromising cerebral perfusion. We hypothesized that sudden BB discontinuation might inadvertently lead to an increased incidence of composite cardiac abnormalities and higher in-hospital mortality in patients presenting with nontraumatic SAH.

Recommended Citation

Okabe, MD, Toshimasa; Jeyabalan, MD, Anushya; Leiby, PhD, Benjamin E.; Rincon, MD, Fred; and Kraft, MD, Walter K., "Impact of Preadmission Beta-blocker Use on Cardiac Abnormalities and In-hospital Mortality in Patients with Aneurysmal Subarachnoid Hemorrhage" (2014). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 55.
https://jdc.jefferson.edu/petfp/55